Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDG-PET in thyroid cancer.

Flavio Crippa1, Alessandra Alessi, Alberto Gerali

  • 1Nuclear Medicine Division, PET Center, National Cancer Institute, Milan, Italy.

Tumori
|February 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radioembolization of hepatocellular carcinoma with <sup>90</sup>Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability.

European journal of nuclear medicine and molecular imaging·2025
Same author

Dosimetric optimization and evaluation of hepatocellular carcinoma treatment effect prediction in Y-90 radioembolization.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2025
Same author

Prevention of falls in hospitalized patients-evaluation of the effectiveness of a monitoring system (Verso Vision) developed with artificial intelligence.

Frontiers in digital health·2025
Same author

Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma.

European journal of nuclear medicine and molecular imaging·2025
Same author

Medium- and Long-Term Effects of COVID-19 in a Population of Patients Admitted to the Intensive Care Unit: Cognitive and Psychological Sequelae and Quality of Life Six Months and One Year after Discharge.

Healthcare (Basel, Switzerland)·2024
Same author

Beauty Therapy to Support Psychosocial Recovery from Oncological Care: A Qualitative Research on the Lived Experience of Women with Breast Cancer Treated with Chemotherapy.

Current oncology (Toronto, Ont.)·2024

Radioiodine scintigraphy is standard for differentiated thyroid cancer (DTC). Newer PET scans offer improved detection in specific cases, aiding treatment decisions for both DTC and medullary thyroid cancer (MTC).

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceuticals

Background:

  • Radioiodine scintigraphy and thyroglobulin (Tg) levels are primary tools for differentiated thyroid cancer (DTC) diagnosis.
  • FDG-PET shows limitations in DTC retaining 131I uptake but is valuable when Tg is measurable and 131I scans are negative.
  • Alternative radiopharmaceuticals like 201Tl, 99mTc-sestamibi, and tetrofosmin offer TSH-independent imaging.

Purpose of the Study:

  • To review the utility of various nuclear medicine techniques in diagnosing and managing differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC).
  • To highlight the evolving role of Positron Emission Tomography (PET) in thyroid cancer follow-up.
  • To compare the effectiveness of different imaging modalities, including novel PET tracers.

Main Methods:

Related Experiment Videos

  • Review of diagnostic nuclear medicine techniques including radioiodine scintigraphy, FDG-PET, 201Tl, 99mTc-sestamibi, tetrofosmin, DMSA, MIBG, and (111)In-pentetreotide scans.
  • Evaluation of FDG-PET sensitivity (70-90%) in identifying Tg-producing lesions in post-operative DTC patients.
  • Assessment of imaging modalities for medullary thyroid cancer (MTC), including FDG-PET and 18F-DOPA.

Main Results:

  • FDG-PET is highly useful in DTC patients with negative 131I scans but elevated Tg, potentially altering treatment plans.
  • For MTC, 99mTc-DMSA, 99mTc-sestamibi, MIBG, and (111)In-pentetreotide are used; FDG-PET is effective for calcitonin-positive patients.
  • 18F-DOPA scans show promise for MTC, potentially surpassing FDG-PET in accuracy.

Conclusions:

  • Nuclear medicine imaging, particularly PET, plays a crucial role in the management of thyroid cancers, offering improved diagnostic capabilities.
  • The choice of imaging modality depends on the specific type of thyroid cancer (DTC vs. MTC) and the clinical context.
  • Emerging PET tracers like 18F-DOPA represent advancements in MTC imaging, offering greater precision.